BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Sponsor
Luminary Therapeutics
Study ID
NCT07771361
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
  • Multiple Myeloma Refractory
  • Multiple Myeloma in Relapse
  • Multiple Myeloma in Remission
  • Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma (NHL)
  • Non-Hodgkin Lymphoma Refractory/ Relapsed
  • Non-Hodgkin Lymphoma, B-cell

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BAFF CAR-T — BIOLOGICAL
    Single infusion of 4×10\^6 cells/kg of LMY-920 (autologous CAR-T cell therapy expressing the BAFF-ligand.)

Study Details

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This Phase 2 study will establish the safety and efficacy profile of LMY-920.

Key Dates

First listed
Aug 18, 2026
Start date
Dec 31, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2030
Completion
Feb 28, 2031

Study Design

Enrollment
90 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LMY-920 Assessment
    Participants will receive a single infusion of 4×10\^6 cells/kg of LMY-920 (autologous CAR-T cell therapy expressing the BAFF-ligand.)

Primary Outcome Measure

To assess the efficacy of LMY-920 in patients with relapsed or refractory B-cell NHL and MM. [ Time Frame: 24 Months ]

Central Contacts

Related Studies